NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Estrogen Receptor-positive Breast CancerProgesterone Receptor-positive Breast CancerStage IV Breast CancerRecurrent Breast Cancer
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 148
- Registration Number
- NCT00057941
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Recurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaAnaplastic Large Cell LymphomaRecurrent Adult Burkitt Lymphoma
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00058019
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
Phase 2
Completed
- Conditions
- Stage IV Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate Cancer
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT00058084
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Phase 1
Completed
- Conditions
- Recurrent Small Lymphocytic LymphomaWaldenström MacroglobulinemiaB-cell Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00058240
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Phase 2
Terminated
- Conditions
- Childhood Diffuse Large Cell LymphomaChildhood Immunoblastic Large Cell LymphomaRecurrent Childhood Large Cell LymphomaB-cell Childhood Acute Lymphoblastic LeukemiaL3 Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaChildhood Burkitt LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Small Noncleaved Cell Lymphoma
- Interventions
- Biological: rituximabBiological: filgrastimOther: laboratory biomarker analysis
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 82
- Registration Number
- NCT00058461
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Sarcosinamide Nitrosourea in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT00004079
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation
Phase 2
Completed
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT00058305
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 1
Completed
- Conditions
- Intraocular MelanomaMelanoma (Skin)
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00058279
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
Phase 1
Completed
- Conditions
- B-cell Chronic Lymphocytic LeukemiaContiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular LymphomaContiguous Stage II Mantle Cell LymphomaContiguous Stage II Marginal Zone LymphomaContiguous Stage II Small Lymphocytic LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaNoncontiguous Stage II Grade 1 Follicular LymphomaNoncontiguous Stage II Grade 2 Follicular Lymphoma
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00058227
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00030368
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath